(Tiper Stock Exchange) – Pierrela global provider to the pharmaceutical industry listed on Euronext Milan, has registered revenues equal to approximately 24.8 million euros in 2022, in line with the approximately 25 million estimated by the Board of Directors in April 2022 and an increase of approximately 36% compared to 31 December 2021, when they amounted to approximately 18.2 million at stand-alone level. L’EBITDA was positive for around 4.9 million euro, up by around 17% compared to the 4.2 million estimated by the Board of Directors and up compared to 31 December 2021 when, again at stand-alone level, it was positive by around 1, 1 million.
L’Net income was equal to approximately 1.4 million euro, in contrast with the net loss of approximately 0.4 million recorded at the stand-alone level as at 31 December 2021.
“The company – commented theAD Fulvio Citaredo – is well represented by the draft financial statements as at 31 December 2022 whose positive equity and economic-financial values, together with the main performance indicators, which are also all positive, are the result of many years in which we have planned and implemented various corporate efficiency, which concerned all the company’s business areas and all aimed at achieving and maintaining medium-long term objectives”.
“And such results have been achieved despite the difficulties and uncertainties which have strongly influenced, and in some cases completely revolutionized, the socio-economic context of reference”, he added.
Pierrel’s Board of Directors has also approved the company budget for the year 2023which forecasts gross revenues of approximately 31 million euros and a positive EBITDA of approximately 6 million euros.